SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Harding Thomas C. (Last) (First) (Middle) C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 (Street) BOULDER CO 80301 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 12/03/2020	3. Issuer Name and Ticker or Trading Symbol Clovis Oncology, Inc. [ CLVS ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) See Remarks	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,210	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	01/10/2024	Common Stock	2,167	73.98	D
Stock Option (right to buy)	(2)	02/27/2024	Common Stock	30,000	78.38	D
Stock Option (right to buy)	(3)	03/02/2025	Common Stock	9,350	79.05	D
Stock Option (right to buy)	(4)	07/01/2025	Common Stock	20,000	85.88	D
Stock Option (right to buy)	(5)	08/25/2026	Common Stock	21,047	22.73	D
Stock Option (right to buy)	(6)	03/01/2027	Common Stock	4,250	59.27	D
Stock Option (right to buy)	(7)	03/01/2028	Common Stock	4,500	58.43	D
Stock Option (right to buy)	(8)	10/30/2029	Common Stock	35,000	3.4	D
Restricted Stock Units	(9)	03/01/2027	Common Stock	516	(13)	D
Restricted Stock Units	(10)	03/01/2028	Common Stock	1,688	(13)	D
Restricted Stock Units	(11)	02/01/2029	Common Stock	14,063	(13)	D
Restricted Stock Units	(12)	01/31/2030	Common Stock	29,000	(13)	D

Explanation of Responses:

1. On January 10, 2014, the reporting person was granted 8,000 options. The options are fully vested and are immediately exercisable.

2. On February 27, 2014, the reporting person was granted 30,000 options. The options are fully vested and are immediately exercisable.

3. On March 2, 2015, the reporting person was granted 9,350 options. The options are fully vested and are immediately exercisable.

4. On July 1, 2015, the reporting person was granted 20,000 options. The options are fully vested and are immediately exercisable.

5. On August 25, 2016, the reporting person was granted 33,675 options. The options are fully vested and are immediately exercisable.

6. On March 1, 2017, the reporting person was granted 4,250 options. The option vested as to 25% of the shares on March 1, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date.

7. On March 1, 2018, the reporting person was granted 4,500 options. The option vested as to 25% of the shares on March 1, 2019, and the remainder vests in substantially equal installments over the 36 months immediately following such date.

8. On October 30, 2019, the reporting person was granted 35,000 options. The option vests as to 25% of the shares on October 30, 2020, and the remainder vests in substantially equal installments over the 36 months immediately following such date.

9. On March 1, 2017, the reporting person was granted 4,125 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2018, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

10. On March 1, 2018, the reporting person was granted 4,500 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

11. On February 1, 2019, the reporting person was granted 25,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

12. On January 31, 2020, the reporting person was granted 29,000 Restricted Stock Units. 25% of such Restricted Stock Units vest on January 31, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

13. Each Restricted Stock Unit represents the right to receive one share of Common Stock.

Remarks:

Senior Vice President and Chief Scientific Officer

	/s/ Thomas C. Harding	12/07/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.